Shionogi & Co., Ltd.

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-06-13 EDT			5-day change	1st Jan Change
2,486.00 ^JPY	+1.14%		+2.54%	+12.03%

05-30	Japan Shares Fall as Tokyo Inflation Hits Two-Year High	MT
05-30	Shionogi & Co., Ltd. Announces Acceptance of New Drug Application for Naldemedine tosilate in China	CI

Shionogi & Co Introduces Covgoze Vaccine for Covid-19 in Japan

Published on 2024-06-24 at 22:31, updated on 2024-06-24 at 22:32

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shionogi & Co., Ltd.

Japan Shares Fall as Tokyo Inflation Hits Two-Year High	05-30	MT
Shionogi & Co., Ltd. Announces Acceptance of New Drug Application for Naldemedine tosilate in China	05-30	CI
Shionogi's Opioid-Induced Constipation Drug Accepted for Review in China	05-30	MT
Shionogi & Co Ltd - Acceptance Of A New Drug Application For Naldemedine, A Treatment For Opioid-Induced Constipation, In China	05-29	RE
Shionogi & Co., Ltd. and Veritas in Silico Inc. Announce Milestone Achievement in Joint Drug Discovery Research of mRNA -Targeted Small Molecules	05-23	CI
Shionogi & Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2025 and for the Year Ending March 31, 2026	05-12	CI
Japan's Nikkei ends higher; NTT Data surges on takeover report	05-08	RE
Japan's Nikkei rises; NTT Data set to surge on takeover report	05-07	RE
Shionogi to Acquire Japan Tobacco's Pharma Business, Take Full Control of Torii Pharmaceutical	05-07	MT
Deals of the day-Mergers and acquisitions	05-07	RE
Deals of the day-Mergers and acquisitions	05-07	RE
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion	05-07	RE
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion	05-07	RE
Japan's Nikkei snaps 7-day winning streak as US tariff worries weigh	05-07	RE
Shionogi & Co: To Launch Tender Offer For Torii Pharmaceutical Shares At 6,350 Yen Per Share	05-07	RE
Japan's Shionogi to buy Torii Pharmaceutical for $1 billion, Nikkei says	05-07	RE
Shionogi To Buy Torii Pharmaceutical For About 150 Billion Yen, Nikkei Says	05-07	RE
Shionogi & Co., Ltd. proposed to acquire 44.1% stake in Torii Pharmaceutical Co., Ltd. from group of sellers for ¥80.7 billion in a tender offer transaction.	05-06	CI
Shionogi & Co., Ltd. agreed to acquire Pharmaceutical business of Japan Tobacco Inc from Japan Tobacco Inc..	05-06	CI
Shionogi Raises Year-End Dividend Forecast to 33 Yen	04-24	MT
StemRIM's Stroke Drug Clears Key Hurdle in Global Trial	04-02	MT
Shionogi & Co Ltd - Shionogi Initiates New Drug Application Submission For Ensitrelvir For Post-Exposure Prophylaxis With U.S. Food And Drug Administration	03-31	RE
Shionogi & Co., Ltd. Initiates New Drug Application Submission for Ensitrelvir for Post-Exposure Prophylaxis with the U.S. Food and Drug Administration	03-31	CI
Shionogi & Co Ltd: Shionogi Submits Supplemental New Drug Application For Ensitrelvir In Japan For Post-Exposure Prophylaxis Of Covid-19	03-26	RE
Shionogi & Co., Ltd. Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Post-Exposure Prophylaxis of Covid-19	03-26	CI

Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.

Employees

4,955

Sector

Pharmaceuticals

Calendar

06-17 - Annual General Meeting

More about the company